Skip to main content

Month: August 2025

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will begin immediately to ensure robust supply and rapid access of this season’s vaccine in pharmacies, hospitals, and clinics across the countryNEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at...

Continue reading

Raymond James Welcomes Ohio Financial Advisors Managing $305 Million in Assets

St. Petersburg, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) — Raymond James (NYSE: RJF) recently welcomed financial advisors Stew Flaherty, AIF®, ChFC®, CLU®, CRC®, and Tami Colvin, CFP®, CRC®, to Raymond James Financial Services (RJFS) – the firm’s independent advisor channel – according to David Sisemore, Midwest divisional director for RJFS.  The duo arrives from Commonwealth Financial Network where they managed approximately $305 million in client assets. Operating as FlahertyColvin in Westerville, Ohio, they provide holistic financial planning and guidance to a variety of clients, specializing in business owners, families and individuals, retirees and pre-retirees and women investors. They are joined by Registered Service Representative Lia Casino, CRC®, and Client Services Associates Erin Bäby and Tamara Adams.  “Raymond James shares...

Continue reading

Cybersecurity Experts Urge Lawmakers to Pursue Lawful Access Solutions Without Compromising Encryption Integrity

HACKENSACK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) — As UK and EU lawmakers reconsider policies to grant law enforcement and investigative agencies (such as Europol) access to encrypted data—often referred to as “lawful access”—Paperclip Inc. is joining a growing chorus of data security experts and privacy advocates warning against the unintended consequences of encryption backdoors. While acknowledging the importance of public safety and the need for law enforcement to investigate criminal activity hidden within encrypted channels or datastores, Paperclip leaders emphasize that weakening encryption for the few creates systemic risks for the many. “Strong encryption is the foundation of digital trust. Undermining it, no matter how well-intentioned, jeopardizes security, privacy, and global confidence in digital infrastructure,” said...

Continue reading

Exosens extends its technology portfolio by signing an agreement to acquire Phasics, leader in high performance cameras based solutions for optical metrology

EXOSENS EXTENDS ITS TECHNOLOGY PORTFOLIO BY SIGNING AN AGREEMENT TO ACQUIRE PHASICS, LEADER IN HIGH PERFORMANCE CAMERAS BASED SOLUTIONS FOR OPTICAL METROLOGY PRESS RELEASEMÉRIGNAC, FRANCE– PALAISEAU, FRANCE, AUGUST 27th, 2025Exosens announces agreement to acquire Phasics, a leader in Wave Front Sensing technology, offering state-of-the-art optics metrology and imaging solutions, from standalone wavefront sensors to fully automated test benches with proprietary software. This acquisition will enhance Exosens’ technological product portfolio, expanding its offering in high performance imaging solutions for defense, industrial control and lifescience. It will also accelerate Phasics’ international growth by leveraging Exosens’ established commercial network notably in instrumentation and semiconductor markets. Exosens continues to execute...

Continue reading

Iceland Seafood International hf: Sterk afkoma á fyrri árshelmingi – tvöföldun hagnaðar fyrir skatta

Sterk afkoma á fyrri árshelmingi – tvöföldun hagnaðar fyrir skatta.  Hagnaður fyrir skatta af reglulegri starfsemi er 331 milljónir ISK (€2.3m) samanborinn við 158 milljónir ISK (€1.1m) 1H 2024 sem er aukning um 173 milljónir ISK (€1.2m) Rekstrartekjur á fyrri árshelming 2025 námu 33,7 milljörðum ISK: (€233.8m), sem er aukning um 10% frá sama tímabili 2024 Framlegð fyrir 1H 2025 er 3,3 milljarður ISK milli (€22.9m) samanborið við 2,7 milljarð (€19m) á sama tíma 2024 EBITDA fyrir 1H 2025 hækkaði í 1,3 milljarð (€9.2m) frá 720 milljónum(€5m) í 1H 2024 EBITDA síðustu 12 mánaða hækkaði um 1,1 milljarð, í 2,9 milljarða (€20.3m) frá 1,8 milljarði (€12,7m) á 1H 2024 Hagnaður fyrstu sex mánaða eftir skatta er 158 milljónir ISK (€1.1m) samanborinn við 101 milljóna (€0.7m) tap fyrir sama tímabil 2024 Hagnaður á hlut fyrir 1H 2025 er 0,05 ISK á...

Continue reading

Iceland Seafood International hf: Strong first-half performance, with Normalised Profit Before Tax doubling year-on-year

Strong first-half performance, with Normalised Profit Before Tax doubling year-on-year Normalised Profit Before Tax: €2.3 million positive, vs. €1.1 million in 1H 2024 1H 2025 Sales: €233.8 million, up 10% from 1H 2024 Net Margin for 1H 2025: €22.9 million, up €3.9 million EBITDA for 1H 2025 was €9.2m up from €5m H1 2024  12-month EBITDA reached €20.3 million, up from €12.7 million in H1 2024 Net Profit: €1.1 million, improved from (€0.7 million loss) in 1H 2024 EPS for 1H 2025: Positive €0.0357 cents per thousand shares, vs. negative €0.0238 in 1H 2024 Total Assets: €251.5 million, down €1.8 million Equity ratio of 30.2% at the end of Q2 2025 vs 28.6% at the end of Q2 2024  2025 Normalised PBT Outlook remains €7.5 million to €9.5 million Group sales for the second quarter reached €114.6 million, an increase...

Continue reading

Fangzhou Posts Strong 1H Revenue and Profit as Physician Network and User Base Expand

HONG KONG, Aug. 27, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, reported a profitable first half of 2025, supported by an expanding user base, higher operating efficiency, and accelerated deployment of AI across its healthcare services and internal operations. Net Profit Swings to Positive as Targeted User Base Unlocks Growth Fangzhou posted revenue of RMB 1.494 billion for the six months ended June 30, up 12.9% from a year earlier. Net profit reached RMB 12.5 million, compared with a loss of RMB 818.7 million in the same period last year. Adjusted net profit also increased 16.8% to RMB 17.6 million, marking a new high. Registered users on the platform grew 15.8% year-on-year to 52.8 million, while monthly active users surged 34.4% to 11.9...

Continue reading

Michelin: Disclosure of trading in own shares – August 27th, 2025

23, Place des Carmes-Déchaux – 63000 CLERMONT-FERRAND Information about securities repurchasing programRegulated informationIssuer social denomination: Michelin – LEI 549300SOSI58J6VIW052 Types of securities: ordinary shares – Code ISIN FR001400AJ45Date : August 27th, 2025Issuer Name Issuer code Transactiondate ISIN Code Daily total volume (in number of actions) Daily weighted average price of shares acquired PlatformCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 27.08.2025 FR001400AJ45 436 917 31.9363 euros Over-the-counterIssuer Name Issuer code PSIName Issuer Code Transaction dateISIN Code Unit Price Currency Quantity bought Platform Transaction reference number Buyback objectiveCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 CA-CIB 1VUV7VQFKUOQSJ21A208 27.08.2025 FR001400AJ45 31.9363 Euro 436...

Continue reading

Ramsay Sante : Provisional annual Results at the end of June 2025

        PRESS RELEASE                 Paris, 27th August 2025 Provisional annual results at the end of June 2025Revenue growth of 4.7% and Group EBITDA up 1.7% despite reduction in public funding; secured long term financing framework Activity growth and cost control mitigate low French tariffsGroup revenue increased by 4.7% to €5.2bn supported by activity volume growth and former Cosem primary care centres acquired in June 2024. Revenue growth of 2.7% on a like-for-like basis. Group EBITDA reported for the year ended June 2025 was up 1.7% or €10m at €621m, despite the (€53m) decrease in French grants and other funding, as well as industry-wide inflation continuing to be under-funded by governments. French tariffs experienced a +2,2% increase in French MSO activities from July 2024 from the CICE coefficient cancelation, however not applied...

Continue reading

STG Global Finance B.V. – Interim Report, Scandinavian Tobacco Group A/S

Company Announcement No. 03/2025  Copenhagen, 27 August 2025 STG Global Finance B.V. – Interim Report, Scandinavian Tobacco Group A/S On 27 August 2025, Scandinavian Tobacco Group A/S published its interim report for 1 April – 30 June 2025. The Annual Report and company announcement of Scandinavian Tobacco Group A/S relating to the published reports are available at: https://www.st-group.com/investor/. For further information, please contact: Torben Sand, Director of IR & Communication, phone +45 5084 7222, torben.sand@st-group.com.Eliza Dabbagh, IR & Communications, phone +45 5080 7619, eliza.michael@st-group.com.AttachmentSTG NV – CA no 3 2025

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.